DOP2019000047A - Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres - Google Patents

Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres

Info

Publication number
DOP2019000047A
DOP2019000047A DO2019000047A DO2019000047A DOP2019000047A DO P2019000047 A DOP2019000047 A DO P2019000047A DO 2019000047 A DO2019000047 A DO 2019000047A DO 2019000047 A DO2019000047 A DO 2019000047A DO P2019000047 A DOP2019000047 A DO P2019000047A
Authority
DO
Dominican Republic
Prior art keywords
treatment
inflammatory
autoimmunity
imidazol
compounds derived
Prior art date
Application number
DO2019000047A
Other languages
English (en)
Inventor
Louise Jones Katherine
Baxter Andrew
Alexander Brown John
Hirst David
Humphreys Philip
Kantibhai Patel Vipulkumar
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2019000047A publication Critical patent/DOP2019000047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Compuestos de fórmula (I) y sales de los mismos: (I) en la que R1, R2, R3 y a son como se definen en el presente documento. Se ha descubierto que los compuestos de fórmula (I) y sales de los mismos inhiben la unión de la familia BET de proteínas que contienen bromodominios a, por ejemplo, residuos de lisina acetilados y, por tanto, pueden tener uso en terapia, por ejemplo, en el tratamiento de enfermedades autoinmunitarias e inflamatorias, tales como artritis reumatoide; y cánceres.
DO2019000047A 2016-09-02 2019-02-28 Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres DOP2019000047A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614934.6A GB201614934D0 (en) 2016-09-02 2016-09-02 Chemical compounds

Publications (1)

Publication Number Publication Date
DOP2019000047A true DOP2019000047A (es) 2019-03-15

Family

ID=57140084

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000047A DOP2019000047A (es) 2016-09-02 2019-02-28 Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres

Country Status (24)

Country Link
US (1) US20190175571A1 (es)
EP (1) EP3507283A1 (es)
JP (1) JP2019526577A (es)
KR (1) KR20190042701A (es)
CN (1) CN109790147A (es)
AR (1) AR109487A1 (es)
AU (1) AU2017317724A1 (es)
BR (1) BR112019004241A2 (es)
CA (1) CA3035312A1 (es)
CL (1) CL2019000538A1 (es)
CO (1) CO2019001871A2 (es)
CR (1) CR20190106A (es)
DO (1) DOP2019000047A (es)
EA (1) EA201990410A1 (es)
GB (1) GB201614934D0 (es)
JO (1) JOP20190029A1 (es)
MA (1) MA46085A (es)
MX (1) MX2019002491A (es)
PE (1) PE20190478A1 (es)
PH (1) PH12019500460A1 (es)
SG (1) SG11201901673SA (es)
TW (1) TW201817724A (es)
UY (1) UY37393A (es)
WO (1) WO2018041947A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190101A (es) 2016-09-02 2019-07-04 Ironwood Pharmaceuticals Inc Estimuladores de sgc
CN111686107B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
CN111588725B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途
CN111588721B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途
CN111686114B (zh) * 2020-07-16 2021-06-08 中国农业科学院兰州兽医研究所 化合物i-bet-762用于制备预防或治疗非洲猪瘟药物的新用途
WO2024018423A1 (en) * 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors
CN117257964B (zh) * 2023-10-25 2024-04-02 苏州大学 基于碳酸氢铵的微波诱导吲哚美辛原位无定形化增溶技术

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4034060A1 (de) * 1990-10-26 1992-04-30 Basf Ag Biskationische azofarbstoffe
DE19809994B4 (de) * 1997-03-19 2006-02-09 Basf Ag Clathrate von Bis-[6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(phen-4-ylazo)-pyridin-2-on]ethylen
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
JP4388997B2 (ja) * 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
CN102015686B (zh) * 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
CA2726588C (en) * 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN104788423B (zh) * 2015-03-13 2016-10-26 成都理工大学 一种新的囊性纤维化跨膜传导调节因子抑制剂
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds

Also Published As

Publication number Publication date
TW201817724A (zh) 2018-05-16
PH12019500460A1 (en) 2019-12-16
WO2018041947A1 (en) 2018-03-08
UY37393A (es) 2018-03-23
JOP20190029A1 (ar) 2019-02-25
JP2019526577A (ja) 2019-09-19
EP3507283A1 (en) 2019-07-10
PE20190478A1 (es) 2019-04-04
US20190175571A1 (en) 2019-06-13
CL2019000538A1 (es) 2019-05-17
CO2019001871A2 (es) 2019-03-08
CA3035312A1 (en) 2018-03-08
EA201990410A1 (ru) 2019-09-30
MX2019002491A (es) 2019-07-08
SG11201901673SA (en) 2019-03-28
GB201614934D0 (en) 2016-10-19
CN109790147A (zh) 2019-05-21
KR20190042701A (ko) 2019-04-24
AR109487A1 (es) 2018-12-12
CR20190106A (es) 2019-05-02
BR112019004241A2 (pt) 2019-06-04
MA46085A (fr) 2019-07-10
AU2017317724A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
DOP2017000213A (es) Derivados de bencimidazol como inhibidores de bromodominio
DOP2019000047A (es) Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CO2017011484A2 (es) Inhibidores de bromodominio
CR20160229A (es) Inhibidires de bromodominio
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
SV2016005316A (es) Compuestos y composiciones para inducir condrogénesis
CL2017000659A1 (es) Inhibidores de histona desmetilasa
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
CR20150593A (es) Potenciador de inhibidores del homólogo de zeste
EA202091923A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr